Exenatide Once Weekly vs Placebo: Secondary Efficacy Outcome All-Cause Mortality

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.0689	0.0634	0.0749	wilson	ClinicalTrials.gov
Risk in group 2	0.079	0.073	0.0853	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.01	-0.0185	-0.00159	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.873	0.778	0.979	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.863	0.763	0.977	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Exenatide Once Weekly than on Placebo	99.6	54.1	629	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Exenatide Once Weekly	Exenatide 2mg once weekly subcutaneous injections	507	7,356	OG001	ClinicalTrials.gov
Group 2	Placebo	Matching placebo subcutaneous injections	584	7,396	OG000	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Secondary Efficacy Outcome All-Cause Mortality	ClinicalTrials.gov
Description	The secondary efficacy outcome variable is defined as the all-cause mortality (deaths). The number of participants who had an event is reported in the results.	ClinicalTrials.gov
Time frame	Time to first event. Information collected during study period (anticipated to be up to 7.5 years).	ClinicalTrials.gov
Population	ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus	ClinicalTrials.gov
NCT number	NCT01144338	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Type 2 Diabetes Mellitus	ClinicalTrials.gov
Interventions	Exenatide Once Weekly, Placebo	ClinicalTrials.gov
Lead sponsor	AstraZeneca	ClinicalTrials.gov
Results first posted	2018-08-08	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT01144338?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.